Research programme: adrenergic beta 3 receptor agonists - Eli Lilly

Drug Profile

Research programme: adrenergic beta 3 receptor agonists - Eli Lilly

Latest Information Update: 03 Apr 2009

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Benzimidazoles; Obesity therapies
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists; Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity; Syndrome X; Type 2 diabetes mellitus

Most Recent Events

  • 31 Mar 2009 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 31 Mar 2009 No development reported - Preclinical for Obesity in USA (unspecified route)
  • 16 Apr 2007 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top